Trials / Completed
CompletedNCT03785522
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia
A Prospective Non-interventional Study Investigating the Treatment Effect of Tresiba® in Adult Patients With Type 2 Diabetes in Saudi Arabia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 597 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect information on how Tresiba® works in real world patients. Patients will get Tresiba® as prescribed to them by their study doctor. The study will last for about 6 to 8 months. Patients will be asked questions about their health and diabetes treatment as part of their normal study doctor's appointment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin degludec | Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter. |
Timeline
- Start date
- 2018-12-23
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
- First posted
- 2018-12-24
- Last updated
- 2021-06-04
Locations
21 sites across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT03785522. Inclusion in this directory is not an endorsement.